tert-butyl N-[(2S)-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl]carbamate | 911787-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-[(2S)-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl]carbamate
• CAS: 911787-18-3
• 化学式: C₁₅H₁₈F₃NO₃
• 分子量: 317.308
• InChiKey: BJKSPPJYOPVHSI-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(2S)-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl]carbamate 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-Amino-N-[(S)-2-ethylcarbamoyl-2-hydroxy-1-(4-trifluoromethyl-benzyl)-ethyl]-3-methyl-butyramide
  参考文献：
  名称：

  Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy

  摘要：

  Dipeptide-derived alpha-keto-amide compounds with potent calpain inhibitory activity have been identified. These reversible covalent inhibitors have IC50 values down to 25 nM and exhibit greatly improved activity in muscle cells compared to the reference compound MDL28170. Several novel calpain inhibitors have shown positive effects on histological parameters in an animal model of Duchenne muscular dystrophy demonstrating their potential as a treatment option for this fatal disease. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.064
• 作为产物：
  描述：

  BOC-L-4-三氟甲基苯丙氨酸 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 tert-butyl N-[(2S)-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl]carbamate
  参考文献：
  名称：

  Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy

  摘要：

  Dipeptide-derived alpha-keto-amide compounds with potent calpain inhibitory activity have been identified. These reversible covalent inhibitors have IC50 values down to 25 nM and exhibit greatly improved activity in muscle cells compared to the reference compound MDL28170. Several novel calpain inhibitors have shown positive effects on histological parameters in an animal model of Duchenne muscular dystrophy demonstrating their potential as a treatment option for this fatal disease. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.064

文献信息

• Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof
  申请人：Eickmeier Christian

  公开号：US20060223759A1

  公开（公告）日：2006-10-05

  The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R 1 to R 15 , A, B, L, i as well as X 1 -X 4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

  本发明涉及通式（I）的取代1,2-乙二胺化合物，其中基团R1至R15，A，B，L，i以及X1-X4如规范和权利要求中所定义，并且其用于治疗阿尔茨海默病（AD）和类似疾病。
• Heterocyclic modulators of PKB
  申请人：ZENG Qingping

  公开号：US20090275592A1

  公开（公告）日：2009-11-05

  The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种公式I的杂环化合物及其组合物，其中变量具有本文所提供的定义，其在治疗由蛋白激酶B（PKB）介导的疾病方面具有用途。本发明还涉及这种化合物和组合物在治疗与异常细胞生长、癌症、炎症和代谢紊乱相关的疾病状态方面的治疗用途。
• Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists
  作者：Alice Valentini、Katrine Schultz-Knudsen、Anders Højgaard Hansen、Argyro Tsakoumagkou、Laura Jenkins、Henriette B. Christensen、Asmita Manandhar、Graeme Milligan、Trond Ulven、Elisabeth Rexen Ulven

  DOI：10.1021/acs.jmedchem.2c01935

  日期：2023.5.11

  The free fatty acid receptor 2 (FFA2), also known as GPR43, mediates effects of short-chain fatty acids and has attracted interest as a potential target for treatment of various metabolic and inflammatory diseases. Herein, we report the results from bioisosteric replacement of the carboxylic acid group of the established FFA2 antagonist CATPB and SAR investigations around these compounds, leading to

  游离脂肪酸受体 2 (FFA2)，也称为 GPR43，介导短链脂肪酸的作用，作为治疗各种代谢和炎症疾病的潜在靶点而引起人们的兴趣。在此，我们报告了已建立的 FFA2 拮抗剂 CATPB 的羧酸基团的生物等排取代结果以及围绕这些化合物的 SAR 研究，从而发现了第一个高效 FFA2 拮抗剂，其中优选化合物 TUG-2304 ( 16l )在 cAMP 和 GTPγS 测定中IC 50值为 3-4 nM，具有良好的理化和药代动力学特性，并且能够完全抑制丙酸诱导的中性粒细胞迁移和呼吸爆发。
• SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1866034A1

  公开（公告）日：2007-12-19
• SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF
  申请人：EICKMEIER Christian

  公开号：US20100204160A1

  公开（公告）日：2010-08-12

  The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R 1 to R 15 , A, B, L, i as well as X 1 -X 4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.